NCT07060365 - A Master Protocol Study to Investigate Biomarker-guided Novel Anticancer Agent(s) as Monotherapy or Combination Therapy in Participants With Advanced/Recurrent Ovarian Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 2, 2025

Primary Completion Date

May 29, 2029

Study Completion Date

May 29, 2029

Conditions

Advanced/Recurrent Ovarian Cancer

Interventions

DRUG

Saruparib

Participants will receive saruparib via oral administration.

Trial Locations (23)

8035

NOT_YET_RECRUITING

Research Site, Barcelona

10016

WITHDRAWN

Research Site, New York

10065

WITHDRAWN

Research Site, New York

20132

RECRUITING

Research Site, Milan

20141

NOT_YET_RECRUITING

Research Site, Milan

20159

RECRUITING

Research Site, Milan

20162

NOT_YET_RECRUITING

Research Site, Milan

20900

NOT_YET_RECRUITING

Research Site, Monza

46010

NOT_YET_RECRUITING

Research Site, Valencia

46026

NOT_YET_RECRUITING

Research Site, Valencia

48100

RECRUITING

Research Site, Ravenna

53226

WITHDRAWN

Research Site, Milwaukee

57105

RECRUITING

Research Site, Sioux Falls

73104

NOT_YET_RECRUITING

Research Site, Oklahoma City

87109

RECRUITING

Research Site, Albuquerque

92835

RECRUITING

Research Site, Fullerton

98109

NOT_YET_RECRUITING

Research Site, Seattle

00168

RECRUITING

Research Site, Rome

410-769

RECRUITING

Research Site, Goyang

03080

RECRUITING

Research Site, Seoul

08308

NOT_YET_RECRUITING

Research Site, Seoul

135-720

RECRUITING

Research Site, Seoul

08028

RECRUITING

Research Site, Barcelona